title: Maintenance of glial plasticity with aging in C-6 glial cells and normal astrocytes in culture: responsiveness to opioid peptides.
abstract: In this study we used as glial cell models, early and late passage C-6 glial cells, 2B clone, and advanced passages of glial cells derived from aged mouse cerebral hemispheres (MACH) to examine responsiveness to opioids. We have previously reported that early passage C-6 glial cells, 2B clone, are bipotential and can be geared toward oligodendrocyte or astrocytic expression, whereas late passage C-6 glial cells are astrocytic. In addition, MACH cultures have been previously characterized and consist of astrocytes type 1 and 2, some oligodendrocytes, and few glial precursors. In this study, early passage (17-20) and late passage (106-108) C-6 glial cells or MACH cells of passages 16-19 were grown from plating time until harvesting, day 7 or 8, in DMEM + 10% FBS in the presence or absence of opioid peptides, Leu-enkephalin (10(-8) to 10(-10) M) or its synthetic analog, dalargin (Tyr-D-Ala-Gly-Phe-Leu-Arg; 10(-8) to 10(-10) M). We examined for the activities of glutamine synthetase (GS) and cyclic nucleotide phosphohydrolase (CNP), enzyme markers for astrocytes and oligodendrocytes, respectively. We found that CNP activity was markedly increased in the early passage following opioid treatment, indicative of a shift to oligodendrocytic expression. In the late passage cells, already committed to astrocytic expression, opioid treatment enhanced GS activity suggesting that astrocytes respond to opioids. GS activity was markedly increased in MACH cultures grown in the presence of opioids with no changes in CNP. Thus, type 1 astrocytes, the predominant glial type in MACH cultures, responded to opioids.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Psychiatry, University of Colorado School of Medicine, Denver 80262.
authors.forename: M
authors.initials: M
authors.lastname: Kozlova
authors.forename: S
authors.initials: S
authors.lastname: Kentroti
authors.forename: A
authors.initials: A
authors.lastname: Vernadakis
mesh_terms: D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000096:biosynthesis; D000595:Amino Acid Sequence; D000818:Animals; D001253:Astrocytes / Q000187:drug effects* / Q000201:enzymology; D016922:Cellular Senescence; D004723:Endorphins / Q000494:pharmacology*; D004743:Enkephalin, Leucine / Q000494:pharmacology; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives / Q000494:pharmacology; D005910:Glioma / Q000378:metabolism; D005974:Glutamate-Ammonia Ligase / Q000096:biosynthesis; D051379:Mice; D008809:Mice, Inbred C3H; D008969:Molecular Sequence Data; D009419:Nerve Tissue Proteins / Q000378:metabolism; D009457:Neuroglia / Q000187:drug effects* / Q000201:enzymology; D009473:Neuronal Plasticity / Q000187:drug effects*; D009836:Oligodendroglia / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D004723:Endorphins; D009419:Nerve Tissue Proteins; D004743:Enkephalin, Leucine; D016308:Enkephalin, Leucine-2-Alanine; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D005974:Glutamate-Ammonia Ligase; C040996:enkephalin-Leu, Ala(2)-Arg(6)-